Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ipilimumab and Sintilimab for Rectal Cancer
NCT07879586Phase 3Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
A Phase 3 trial of ipilimumab in rectal cancer. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ipilimumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07879586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879586.